Sign in
Not yet taking people in United StatesNo phase

Positron Emission Tomography and Organ-Specific Changes in Participants Co-Enrolled in NIH Studies of Plasmodium Vivax Controlled Human Malaria Infection

Key facts

Who runs it
National Institute of Allergy and Infectious Diseases (NIAID)
Where
Bethesda, United StatesSee the site
Trial code
Status
Not yet recruiting
People taking part
45 people, planned
Starts
23 Nov 2026
Expected to end
1 Nov 2030
Type of study
Interventional
Treatments tested
  • 18F-fluorodeoxyglucose-positron emission tomography/computed tomography scan
Record updated
18 November 2026

Who can take part

Age
18 years to 54 years
Sex
Women and men
Healthy volunteers
Cannot take part
Show the full registry criteria (13)Hide the full registry criteria

Who cannot take part

  • Currently undergoing therapy with drugs that, in the judgment of the investigators, may interfere with biodistribution of FDG (e.g., insulin that cannot be held or metformin that cannot be stopped for 48 hours prior to each FDG-PET/CT.)
  • History of splenectomy
  • History of diabetes or poorly controlled blood sugar, in the judgement of the investigators, would prevent completion of FDG-PET/CT scan
  • An individual who meets any of the following criteria will be excluded from participation in this study:
  • Pregnancy or lactation
  • Any other finding that, in the judgment of the investigator, would interfere with, or serve as a contraindication to, protocol adherence, assessment of safety, or a participant s ability to give informed consent, or increase the risk of having an adverse outcome from; participating in the study; Co-enrollment guidelines: Co-enrollment in other trials is restricted, other than enrollment on the LMIV CHMI trials described above and NIH protocol 17I0122, NIAID Centralized Sequencing Protocol. Study staff should be notified of co-enrollment on any other protocol as it may require the approval of the principal investigator

Other criteria

  • INCLUSION CRITERIA; In order to be eligible to participate in this study, an individual must meet all of the following criteria:
  • Aged >=18 and <=54 years
  • Able to provide informed consent
  • Co-enrolled in NIH protocol IRB001970, "Phase 1 study of induced blood-stage malaria in healthy malaria-naive adults to assess the safety and infectivity of Plasmodium vivax challenge agent and evaluate transmission in mosquito feeding assays" or IRB002627, "Phase 1/2 study of transmission-blocking vaccine Pvs230D1-EPA/Matrix-M in healthy malaria-naive adults using a Plasmodium vivax controlled human malaria infection model."
  • Willing to allow long-term storage of study samples for future research
  • Individuals of childbearing potential must agree to use an acceptable method of contraception from 1 month prior to the first FDG-PET/CT scan through the end of the study. Participants will also be expected to adhere to the strictest of the contraception; requirements of any studies they are co-enrolled in. Acceptable methods of contraception include the following:; A barrier method (e.g., consistent condom use) combined with an oral contraceptive pill, hormonal patch, or ring; Parenteral hormonal contraceptive implant or an intrauterine device; Participants who otherwise are not at risk of becoming pregnant, at the judgement of the investigator will not be required to use contraception. Such participants may include those:; Having undergone hysterectomy, bilateral oophorectomy, or bilateral fallopian tube ligation; Having reached menopause (age >=45 years plus no menses for 12 consecutive months without an alternative medical cause); Having exclusive same-sex relations or committed longstanding abstinence due to a serious life choice; Having an exclusive male partner who has undergone vasectomy at least 4 months prior
  • Participants need to have established medical care with a primary care doctor or be willing to establish care in case medically relevant findings on their imaging require follow-up

Eligibility questionnaire

From the criteria published for this trial, to help you prepare for a talk with your doctor or the study team. We do not tell you a result. Only the study team can say whether you can take part.

  • Age
  • Malaria

Where in United States

  • National Institutes of Health Clinical CenterBethesda, United StatesContact: Shanan Immel, M.D.Not yet recruiting

About the trial

What the trial wants to find out

Background:

Read full original descriptionShow less

Malaria is a serious disease caused by parasites spread by mosquitoes. To better diagnose and treat malaria, researchers need to learn more about where the parasites go when they enter a person's body. They want to see if they can locate the malaria parasites in the body using imaging scans.

Objective:

To learn whether imaging scans can locate parasites in people with malaria.

Eligibility:

Healthy people aged 18 to 54 years. They must be enrolled in protocol IRB001970 or IRB002627 for controlled malaria infection.

Design:

Participants will be screened. They will have blood drawn and a physical exam, including an abdominal exam to check the size of their spleen.

Participants for this study will have 2 or 3 positron emission tomography/computed tomography (PET/CT) scans: The first will be about 3 days before they are deliberately infected with malaria for a different study. The second will be about 13 days later, while they have the disease. The third scan is optional; it will be done about 3 and 1/2 weeks after the second scan.

For each scan, participants will receive a radioactive tracer called fluorodeoxyglucose (FDG). FDG will be injected through a tube inserted into a vein. They will lie on a table that slides through a doughnut-shaped machine. PET/CT uses x-rays to create images of the inside of the body.

All participants will have a follow-up visit about 3 and 1/2 weeks after the second scan. The blood draw and physical exam will be repeated. This visit may be combined with the third scan for those who choose it.

The group in the trial

  • Healthy Volunteers who are co-enrolled in a P. vivax CHMI studyTreatment being tested

    Healthy Volunteers are co-enrolled in a Plasmodium vivax challenge model protocol at the NIH Clinical Center.

    Treatment: 18F-fluorodeoxyglucose-positron emission tomography/computed tomography scan

Next steps

For your doctor

Doctor ask sheet

A PDF for your doctor: what this trial tests, who can take part, and 2 eligibility questions with room for answers and notes.

Download the PDF

PDF, US Letter, 1 to 2 pages. A4 size

For the study team

Questions to ask the study team

  1. How often do I need to come in, and for how long each time?
  2. Are travel costs paid?
  3. Can I keep my own doctor?
  4. What happens if I want to stop?

Contact the study team: see the registry record → Contacts and Locations

Data and sources

Registry record
Listed on ClinicalTrials.gov.How to verify a trial in the registry
Criteria questions
Built from NCT07859800, who can take part
Record updated
18 November 2026